BMY Bristol-Myers Squibb Company NYQ · Healthcare · USD Watching
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for… Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Price history
Loading price data…
Recent news
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
Zacks ·
Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More.
Barrons.com ·
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
Zacks ·
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
MT Newswires ·
Why Has AbbVie Gone Quiet About Humira?
Trefis ·
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes
Trefis ·
Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?
Insider Monkey ·
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
Zacks ·
Details
IndustryDrug Manufacturers - General
ExchangeNYQ
CurrencyUSD
Next-day prediction
↓ Down hold

2% confidence

2-day prediction
↑ Up

8% confidence

Technical signals

Price & volume indicators the model reads, as of 2026-09-10. These are computed from recent trading — momentum, trend, volatility and volume — and feed the prediction above.

Momentum
RSI (14) 0.429
Stochastic %K (14) 0.004
Stochastic %D (14) 0.037
Stochastic RSI (14) 0.000
Trend
Price vs SMA (20) -0.037
Price vs EMA (26) -0.024
Price vs WMA (20) -0.038
PPO (12/26/9) 0.008
Volatility
Bollinger %B (20/2) 0.054
Bollinger Bandwidth (20/2) 0.084
ATR % (14) 0.024
Keltner position (20/10/2) 0.167
Volume
OBV change (20) 0.216
Money Flow Index (14) 0.631
Chaikin Money Flow (20) 0.087
Money Flow Multiplier -0.966
Returns & Statistics
Return (1) -0.010
Return (2) -0.015
Overnight gap 0.008
Intraday range 0.019

Technical indicators — BMY

These price/volume technical indicators are computed from recent trading and are part of what the prediction model reads for BMY. Values are as of 2026-09-10 (coverage 100% — the share of indicators with enough price history to compute). A value of 0 with low coverage usually means "not enough history yet", not a true reading.

Momentum

Oscillators that gauge how strongly and how fast the price has been moving — used to spot overbought/oversold conditions and shifts in drive.

RSI (7)
Relative Strength Index: 0–1 scale of recent gains vs losses. Above ~0.7 is 'overbought' (may be due to cool off); below ~0.3 'oversold'.
 0.2800
RSI (14)
Relative Strength Index: 0–1 scale of recent gains vs losses. Above ~0.7 is 'overbought' (may be due to cool off); below ~0.3 'oversold'.
 0.4289
RSI (21)
Relative Strength Index: 0–1 scale of recent gains vs losses. Above ~0.7 is 'overbought' (may be due to cool off); below ~0.3 'oversold'.
 0.4856
Stochastic %K (14)
Where the close sits within its recent high–low range (0 = at the low, 1 = at the high).
 0.0044
Stochastic %D (14)
A 3-day smoothing of Stochastic %K — the slower signal line.
 0.0368
Stochastic %K (9)
Where the close sits within its recent high–low range (0 = at the low, 1 = at the high).
 0.0044
Stochastic %D (9)
A 3-day smoothing of Stochastic %K — the slower signal line.
 0.0392
Stochastic RSI (14)
RSI rescaled to where it sits in its own recent range (0–1) — a more sensitive overbought/oversold reading.
 0.0000
Williams %R (14)
Like the Stochastic, the close's position in the recent range (0 = low, 1 = high).
 0.0044
CCI (20)
Commodity Channel Index: how far price is from its average, squashed to about −1…+1. High = unusually strong, low = unusually weak.
 -0.8388
CCI (40)
Commodity Channel Index: how far price is from its average, squashed to about −1…+1. High = unusually strong, low = unusually weak.
 -0.1925
Rate of Change (5)
Log return over the lookback — simple momentum (positive = up).
 -0.0595
Rate of Change (10)
Log return over the lookback — simple momentum (positive = up).
 -0.0582
Rate of Change (20)
Log return over the lookback — simple momentum (positive = up).
 0.0008
KDJ %K (9)
Smoothed position of the close in its recent range (0–1).
 0.2112
KDJ %D (9)
A further smoothing of KDJ %K.
 0.4064
KDJ %J (9)
The fast, sensitive leg of KDJ — exaggerates turns.
 -0.1773
Ultimate Oscillator (7/14/28)
Buying pressure blended across short, medium and long windows (0–1).
 0.4136
True Strength Index (25/13)
Double-smoothed momentum, about −1…+1 (positive = upward drive).
 0.0930

Trend

Moving-average and directional measures of which way the price is trending and how strong that trend is.

Price vs SMA (10)
How far the close is above (+) or below (−) its simple moving average, as a fraction.
 -0.0380
Price vs SMA (20)
How far the close is above (+) or below (−) its simple moving average, as a fraction.
 -0.0375
Price vs SMA (50)
How far the close is above (+) or below (−) its simple moving average, as a fraction.
 0.0076
Price vs SMA (100)
How far the close is above (+) or below (−) its simple moving average, as a fraction.
 0.0655
Price vs SMA (200)
How far the close is above (+) or below (−) its simple moving average, as a fraction.
 0.1068
Price vs EMA (12)
How far the close is above/below its exponential moving average (weights recent prices more).
 -0.0317
Price vs EMA (26)
How far the close is above/below its exponential moving average (weights recent prices more).
 -0.0241
Price vs EMA (50)
How far the close is above/below its exponential moving average (weights recent prices more).
 0.0022
Price vs EMA (200)
How far the close is above/below its exponential moving average (weights recent prices more).
 0.1219
Price vs WMA (20)
How far the close is above/below its weighted moving average.
 -0.0382
PPO (12/26/9)
Percentage Price Oscillator — MACD expressed as a percent so it compares across stocks. Positive = short-term momentum above long-term.
 0.0078
PPO Signal (12/26/9)
The smoothed signal line of the PPO.
 0.0168
PPO Histogram (12/26/9)
PPO minus its signal line — momentum of the momentum.
 -0.0089
ADX (14)
Trend strength on a 0–1 scale (direction-agnostic). Higher = a stronger trend.
 0.3336
+DI (14)
Strength of upward directional movement (0–1).
 0.2125
−DI (14)
Strength of downward directional movement (0–1).
 0.2126
Aroon Up (25)
How recently a new high was made (1 = just now).
 0.4000
Aroon Down (25)
How recently a new low was made (1 = just now).
 0.2000
Aroon Oscillator (25)
Aroon Up minus Down — positive favours an uptrend.
 0.2000
Parabolic SAR distance
How far price is from the trailing stop-and-reverse level, as a fraction of price.
 -0.0753
Parabolic SAR side
+1 when price is above the SAR (uptrend), −1 below.
 -1.0000
Vortex +VI (14)
Strength of upward trend movement (centred at 0).
 -0.0973
Vortex −VI (14)
Strength of downward trend movement (centred at 0).
 0.0584
Vortex difference (14)
+VI minus −VI — positive favours an uptrend.
 -0.1557
MA slope (50/20)
The recent slope of a moving average (positive = rising trend).
 0.0735

Volatility

How much the price is swinging around — wide bands and high readings mean larger, riskier moves.

Bollinger %B (20/2)
Where price sits within its Bollinger Bands (0 = lower band, 1 = upper). Above 1 or below 0 is an extended move.
 0.0542
Bollinger Bandwidth (20/2)
How wide the bands are relative to price — bigger means more volatile.
 0.0842
ATR % (14)
Average True Range as a percent of price — typical daily swing size.
 0.0235
Keltner position (20/10/2)
Where price sits within its Keltner Channel (0–1).
 0.1670
Keltner width (20/10/2)
Width of the Keltner Channel relative to price.
 0.0884
Donchian position (20)
Where price sits within its recent high–low channel (0–1).
 0.1330
Donchian width (20)
Width of the recent high–low channel relative to price.
 0.0857
Realized volatility (10)
Standard deviation of recent daily returns — how jumpy the stock has been.
 0.0128
Realized volatility (20)
Standard deviation of recent daily returns — how jumpy the stock has been.
 0.0164
Realized volatility (60)
Standard deviation of recent daily returns — how jumpy the stock has been.
 0.0181
Chaikin Volatility (10/10)
Whether the daily high–low range is expanding (+) or contracting (−).
 -0.1594
Ulcer Index (14)
A drawdown-based stress measure — higher means deeper/longer dips from recent highs.
 2.8962

Volume

Whether trading activity is confirming the price move — money flowing in or out, and unusually heavy or light volume.

OBV change (20)
On-Balance Volume trend — net volume flowing in (+) or out (−).
 0.2157
Money Flow Index (14)
A volume-weighted RSI (0–1). High = strong buying pressure.
 0.6309
Chaikin Money Flow (20)
Buying vs selling pressure weighted by volume (−1…+1).
 0.0873
Money Flow Multiplier
Where the close finished in the bar's range, the building block of accumulation/distribution (−1…+1).
 -0.9664
Accum/Dist change (20)
Recent change in the Accumulation/Distribution line (buying vs selling pressure).
 0.0873
Price vs VWAP (20)
How far the close is above/below the rolling volume-weighted average price.
 -0.0369
Force Index (13)
Return times relative volume — the push behind a move.
 -0.0093
Ease of Movement (sign) (14)
+1 when price rose easily on light volume, −1 when it fell easily.
 -1.0000
Ease of Movement (z) (14)
How unusual today's ease-of-movement is vs recent days.
 -0.2435
Volume Rate of Change (14)
Log change in volume vs n days ago — a volume surge/lull.
 -0.3791
Volume Rate of Change (25)
Log change in volume vs n days ago — a volume surge/lull.
 -0.7763
Relative Volume (z) (20)
How many standard deviations today's volume is above/below its recent average.
 -0.6238
Relative Volume (z) (50)
How many standard deviations today's volume is above/below its recent average.
 -0.8200
Relative Volume (20)
Today's volume vs its recent average (log scale; >0 = above).
 -0.2054
Relative Volume (50)
Today's volume vs its recent average (log scale; >0 = above).
 -0.4682

Returns & Statistics

Recent returns over several horizons plus statistical shape (skew, fat tails, drawdown, risk-adjusted return).

Return (1)
Log return over the horizon (positive = up).
 -0.0103
Return (2)
Log return over the horizon (positive = up).
 -0.0146
Return (3)
Log return over the horizon (positive = up).
 -0.0470
Return (5)
Log return over the horizon (positive = up).
 -0.0595
Return (10)
Log return over the horizon (positive = up).
 -0.0582
Return (20)
Log return over the horizon (positive = up).
 0.0008
Overnight gap
Open vs the prior close — overnight move.
 0.0079
Intraday range
High minus low as a fraction of price — the day's swing.
 0.0187
True range
True range (gap-aware swing) as a fraction of price.
 0.0187
Return skew (20)
Asymmetry of recent returns — negative means crash-prone tails.
 -0.4761
Return skew (60)
Asymmetry of recent returns — negative means crash-prone tails.
 -0.2164
Return kurtosis (20)
Fat-tailedness of recent returns — high means jumpy/extreme moves.
 -0.2489
Return kurtosis (60)
Fat-tailedness of recent returns — high means jumpy/extreme moves.
 -0.1385
Downside deviation (20)
Volatility of only the negative returns — pure downside risk.
 0.0120
Downside deviation (60)
Volatility of only the negative returns — pure downside risk.
 0.0119
Max drawdown (20)
Largest peak-to-trough drop over the window, as a fraction.
 0.0637
Max drawdown (60)
Largest peak-to-trough drop over the window, as a fraction.
 0.0637
Return/risk (20)
Average return divided by its volatility — recent risk-adjusted return.
 0.0024
Return/risk (60)
Average return divided by its volatility — recent risk-adjusted return.
 0.1259
Return persistence (20)
Whether up days tend to follow up days (+) or reverse (−).
 -0.0269
Return persistence (60)
Whether up days tend to follow up days (+) or reverse (−).
 -0.2233
Price z-score (20)
How many standard deviations the price is from its recent average.
 -1.7382
Price z-score (50)
How many standard deviations the price is from its recent average.
 0.1368
Return z-score (20)
How unusual the latest return is vs recent returns.
 -0.6322
Return z-score (50)
How unusual the latest return is vs recent returns.
 -0.6922
Company locations
Site City, country Conf.
Bristol-Myers Squibb Company — GLEIF legal address GLEIF legal, United States 72%
Bristol-Myers Squibb Company — Wikidata HQ New York City, United States 78%
Latest signals
Loading signals…